Beam Therapeutics Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • BEAM
  • 1d-0.89%
  • 1w-12.35%
  • 1m-27.42%
  • 1y-17.81%
ATH
  • ATH Price$133.60
  • ATH Date2021-07-01
  • % since ATH-80.76%
  • % to ATH419.84%
ATL
  • ATL Price$13.31
  • ATL Date2020-03-16
  • % from ATL93.09%
  • Last Low Price$17.69
  • Last Low Date2023-10-20
  • % From Last Low45.28%
IPO
  • IPO Price$24.00
  • % Current ROI USD107.08%
  • ATH Price$133.60
  • % ROI ATH 100,375.66%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="BEAM"]

Key Data [addtoany]

Current price $25.7
Sector Healthcare
Industry Biotechnology
Today's High/Low $26.415/$25.14
Volume 1,805,465.00
Previous Close $25.93
52 Week High/Low $49.5/$16.95
Market Cap 2,117,384,064.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-5.07
Annualized Dividend $0
$25.7
[addtoany]

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders.
The company has a strategic alliance with Boston Children’s Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.
; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity